Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma

被引:32
作者
Azuaje, Francisco [1 ]
Tiemann, Katja [1 ]
Niclou, Simone P. [1 ]
机构
[1] LIH, Dept Oncol, NorLux Neurooncol Lab, Luxembourg, Luxembourg
关键词
Epidermal growth factor receptor (EGFR); Targeted therapies; Resistance to treatment; Glioblastoma; Systems biology; GROWTH-FACTOR-RECEPTOR; PHASE-II TRIAL; KINASE INHIBITORS; TARGETED THERAPIES; LUNG-CANCER; TYROSINE KINASES; TUMOR-SUPPRESSOR; MUTANT EGFRVIII; GLIOMA; ACTIVATION;
D O I
10.1186/s12964-015-0098-6
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The alteration of the epidermal growth factor receptor (EGFR)-driven signaling network is a characteristic feature of glioblastomas (GBM), and its inhibition represents a treatment strategy. However, EGFR-targeted interventions have been largely ineffective. Complex perturbations in this system are likely to be central to tumor cells with high adaptive capacity and resistance to therapies. We review key concepts and mechanisms relevant to EGFR-targeted treatment resistance at a systems level. Our understanding of treatment resistance as a systems-level phenomenon is necessary to develop effective therapeutic options for GBM patients. This is allowing us to go beyond the notion of therapeutic targets as single molecular components, into strategies that can weaken cancer signaling robustness and boost inherent network-level vulnerabilities.
引用
收藏
页数:13
相关论文
共 50 条
[41]   Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies [J].
Li, Yuzheng ;
Yu, Lili ;
Zhou, Shiyao ;
Zhou, Hua ;
Wu, Qibiao .
ONCOLOGY RESEARCH, 2025, 33 (06) :1363-1376
[42]   EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer [J].
Selenz, Carolin ;
Compes, Anik ;
Nill, Marieke ;
Borchmann, Sven ;
Odenthal, Margarete ;
Florin, Alexandra ;
Braegelmann, Johannes ;
Buettner, Reinhard ;
Meder, Lydia ;
Ullrich, Roland T. .
CANCERS, 2022, 14 (16)
[43]   Dual blockade of EGFR and PI3K signaling pathways offers a therapeutic strategy for glioblastoma [J].
Tongxuan Guo ;
Changyong Wu ;
Junhao Zhang ;
Jiefeng Yu ;
Guoxi Li ;
Hongyan Jiang ;
Xu Zhang ;
Rutong Yu ;
Xuejiao Liu .
Cell Communication and Signaling, 21
[44]   Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer [J].
Farnsworth, Dylan A. ;
Chen, Yankuan T. ;
de Rappard Yuswack, Georgia ;
Lockwood, William W. .
CELLS, 2021, 10 (12)
[45]   EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis [J].
Cao, Xinyu ;
Zhu, Hu ;
Ali-Osman, Francis ;
Lo, Hui-Wen .
MOLECULAR CANCER, 2011, 10
[46]   WNT signaling in glioblastoma and therapeutic opportunities [J].
Lee, Yeri ;
Lee, Jin-Ku ;
Ahn, Sun Hee ;
Lee, Jeongwu ;
Nam, Do-Hyun .
LABORATORY INVESTIGATION, 2016, 96 (02) :137-150
[47]   WNT Signaling as a Therapeutic Target for Glioblastoma [J].
Latour, Michael ;
Her, Nam-Gu ;
Kesari, Santosh ;
Nurmemmedov, Elmar .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
[48]   The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma [J].
Liu, Xuejiao ;
Chen, Xiangyu ;
Shi, Lin ;
Shan, Qianqian ;
Cao, Qiyu ;
Yue, Chenglong ;
Li, Huan ;
Li, Shengsheng ;
Wang, Jie ;
Gao, Shangfeng ;
Niu, Mingshan ;
Yu, Rutong .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
[49]   Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling [J].
Day, Evan K. ;
Sosale, Nisha G. ;
Xiao, Aizhen ;
Zhong, Qing ;
Purow, Benjamin ;
Lazzara, Matthew J. .
CELL REPORTS, 2020, 30 (10) :3383-+
[50]   FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance [J].
Bartel, Courtney A. ;
Parameswaran, Neetha ;
Cipriano, Rocky ;
Jackson, Mark W. .
ONCOTARGET, 2016, 7 (32) :52597-52612